Connetics reiterated at outperform by RBC

RBC Capital Markets analyst Ken Trbovich reiterated Connetics Corp. at outperform, speculative risk, on news of the Food and Drug Administration's approval and expected fourth-quarter launch of Verdeso. The analyst also raised the price target to $15 from $13. Verdeso's label includes the potential to treat patients as young as 3 months of age, perfectly positioning the product for the pediatric market. Look for the stock to rebound to mid-teens and beyond as the company moves past weak third-quarter results and gains approval of additional products, the analyst said. Shares of the Palo Alto, Calif.-based specialty pharmaceutical company were up 7 cents, or 0.68%, at $10.38. (Nasdaq: CNCT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.